Home » Quark to File IND for Eye Disease Rx in September; New Data Shows It May Treat Glaucoma

Quark to File IND for Eye Disease Rx in September; New Data Shows It May Treat Glaucoma

Jul 30, 2009
Premium

By Doug Macron

This article has been updated to include comments from Quark's CEO.

Quark Pharmaceuticals expects to file an investigational new drug application for its siRNA-based eye-disease treatment QPI-1007 sometime in September, RNAi News has learned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Re-Think on Science Standards

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Faster Efforts

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

Graves Wins Top Australian Science Prize

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

This Week in Cell

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.

What's Popular?

In Gene Silencing/Gene Editing

  1. Broad, DuPont Pioneer Partner to Provide Non-Exclusive Licenses to CRISPR IP

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.